Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 15/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | PIK3CG | P48736 | 10/20 | 0.42 |
| ▸ | PIK3CA | P42336 | 9/20 | 0.42 |
| ▸ | PIK3CB | P42338 | 9/20 | 0.42 |
| ▸ | PIK3R1 | P27986 | 8/20 | 0.42 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | NPY1R | P25929 | 1/20 | 0.40 |
| ▸ | NPY2R | P49146 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | PDE4A | P27815 | 1/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.40 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL735178 | 0.93 | PIK3CD (0.45) | PIK3CDALDH1A1HSD17B10RXFP1PIK3CG | |
| SCHEMBL733470 | 0.92 | PIK3CD (0.46) | PIK3CDALDH1A1HSD17B10RXFP1PIK3CG | |
| SCHEMBL734721 | 0.90 | SMN1; SMN2 (0.51) | PIK3CDALDH1A1LMNAMAPT | |
| SCHEMBL735037 | 0.89 | PIK3CG (0.47) | PIK3CDALDH1A1HSD17B10RXFP1PIK3CG | |
| SCHEMBL735268 | 0.86 | L3MBTL1 (0.47) | PIK3CDALDH1A1LMNAL3MBTL1MAPT | |
| SCHEMBL1703914 | 0.85 | PIK3CD (0.56) | PIK3CDALDH1A1PIK3CGPIK3CAPIK3CB | |
| SCHEMBL734969 | 0.84 | RAB9A (0.47) | PIK3CDALDH1A1HSD17B10LMNAL3MBTL1 | |
| SCHEMBL1703724 | 0.83 | PIK3CD (0.37) | PIK3CDALDH1A1PIK3CGPIK3CAPIK3CB | |
| SCHEMBL735101 | 0.82 | LMNA (0.46) | PIK3CDALDH1A1HSD17B10RXFP1LMNA | |
| SCHEMBL735090 | 0.81 | ALDH1A1 (0.44) | PIK3CDALDH1A1LMNANPY1RNPY2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1278748-B1 | INHIBITORS OF HUMAN PHOSPHATIDYL-INOSITOL 3-KINASE DELTA | ICOS CORP (US) | 2011-03-23 | — | — | EP | claimed |
| US-6800620-B2 | CONTACTING LEUKOCYTES, OSTEOCLASTS WITH AN ENZYME INHIBITORS, A 9H-PURIN-3H-QUINAZOLIN-4-ONE DERIVATIVES, TREATING BONE-RESORPTION DISORDER, ANTIPROLIFERATIVE AGENTS TREATING LEUKEMIA CELLS | ICOS | 2004-10-05 | — | — | US | claimed |
| US-20030195211-A1 | Inhibitors of human phosphatidylinositol 3-kinase delta | ICOS CORPORATION | 2003-10-16 | — | — | US | claimed |
| US-12496341-B2 | Methods for reducing anergy in lymphocytes using modulators of MYC | HTYR ACQUISITION LLC (US) | 2025-12-16 | — | — | US | disclosed |
| US-20240156957-A1 | MODULATORS OF MYC, METHODS OF USING THE SAME, AND METHODS OF IDENIFYING AGENTS THAT MODULATE MYC | TAIGA BIOTECHNOLOGIES (ABC), LLC | 2024-05-16 | — | — | US | disclosed |
| US-20220362377-A1 | MODULATORS OF MYC, METHODS OF USING THE SAME, AND METHODS OF IDENTIFYING AGENTS THAT MODULATE MYC | TAIGA BIOTECHNOLOGIES, INC. (US) | 2022-11-17 | — | — | US | disclosed |
| US-11369678-B2 | Compositions and methods for modulating immune cells | TAIGA BIOTECHNOLOGIES, INC. (US) | 2022-06-28 | — | — | US | disclosed |
| EP-3916010-A1 | MODULATORS OF MYC, METHODS OF USING THE SAME AND METHODS OF IDENTIFYING AGENTS THAT MODULATE MYC | Taiga Biotechnologies, Inc. (US) | 2021-12-01 | — | — | EP | disclosed |
| EP-3339321-B1 | MODULATORS OF MYC, METHODS OF USING THE SAME AND METHODS OF IDENTIFYING AGENTS THAT MODULATE MYC | TAIGA BIOTECHNOLOGIES INC (US) | 2021-04-28 | — | — | EP | disclosed |
| US-20200215188-A1 | MODULATORS OF MYC, METHODS OF USING THE SAME, AND METHODS OF IDENTIFYING AGENTS THAT MODULATE MYC | HTYR ACQUISITION LLC | 2020-07-09 | — | — | US | disclosed |
| US-10695349-B2 | Inhibitors of human phosphatidylinositol 3-kinase delta | ICOS CORPORATION (US) | 2020-06-30 | — | — | US | disclosed |
| EP-1939203-A2 | Inhibitors of human phosphatidyl-inositol 3-kinase delta isoform | ICOS Corporation (US) | 2008-07-02 | — | — | EP | disclosed |
| US-20050261317-A1 | Inhibitors of human phosphatidylinositol 3-kinase delta | ICOS CORPORATION (US) | 2005-11-24 | — | — | US | disclosed |
| US-6949535-B2 | for example, 2-(6-aminopurin-9-ylmethyl)-3-(2-chlorophenyl)-6,7-dimethoxy-3H-quinazolin-4-one | ICOS CORPORATION (US) | 2005-09-27 | — | — | US | disclosed |
| US-20040266780-A1 | for example, 2-(6-aminopurin-9-ylmethyl)-3-(2-chlorophenyl)-6,7-dimethoxy-3H-quinazolin-4-one | ICOS CORPORATION | 2004-12-30 | — | — | US | disclosed |
| US-6800620-B2 | CONTACTING LEUKOCYTES, OSTEOCLASTS WITH AN ENZYME INHIBITORS, A 9H-PURIN-3H-QUINAZOLIN-4-ONE DERIVATIVES, TREATING BONE-RESORPTION DISORDER, ANTIPROLIFERATIVE AGENTS TREATING LEUKEMIA CELLS | ICOS | 2004-10-05 | — | — | US | disclosed |
| US-6667300-B2 | Purinyl substituted quinazoline-4-one derivatives | ICOS CORPORATION | 2003-12-23 | — | — | US | disclosed |
| US-20030195211-A1 | Inhibitors of human phosphatidylinositol 3-kinase delta | ICOS CORPORATION | 2003-10-16 | — | — | US | disclosed |
| US-6518277-B1 | Disrupting leukocyte function | ICOS CORPORATION | 2003-02-11 | — | — | US | disclosed |
| US-20020161014-A1 | Purinyl substituted quinazoline-4-one derivatives | ICOS CORPORATION, A DELAWARE CORPORATION | 2002-10-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020161014-A1 | Purinyl substituted quinazoline-4-one derivatives | PIK3CD, PIK3CA, PIK3CG | PIK3CD 1/4885ALDH1A1 4264/4885HSD17B10 4340/4885 |
| US-20050261317-A1 | Inhibitors of human phosphatidylinositol 3-kinase delta | PIK3CD, PIK3R5, PIK3CA | PIK3CD 1/4885ALDH1A1 4744/4885HSD17B10 2301/4885 |
| US-20040266780-A1 | for example, 2-(6-aminopurin-9-ylmethyl)-3-(2-chlorophenyl)-6,7-dimethoxy-3H-quinazolin-4-one | PIK3CD, PIK3CA, PIK3CG | PIK3CD 1/4885ALDH1A1 3454/4885HSD17B10 2966/4885 |
| US-20030195211-A1 | Inhibitors of human phosphatidylinositol 3-kinase delta | PIK3CD, PIK3CA, PIK3CG | PIK3CD 1/4885ALDH1A1 4487/4885HSD17B10 2106/4885 |
| US-10695349-B2 | Inhibitors of human phosphatidylinositol 3-kinase delta | PIK3CD, PIK3CA, PIK3CG | PIK3CD 1/4885ALDH1A1 4628/4885HSD17B10 2243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.